Integra LifeSciences to acquire Acclarent from J&J’s Ethicon for $275m

14 Dec 2023
www.nsmedicaldevices.com
Acquisition
Acclarent is engaged in the development of ENT procedures with a portfolio comprising balloon technologies for sinus dilation, eustachian tube dilation, and surgical navigation systems Integra LifeSciences has entered into an agreement to acquire Acclarent. (Credit: Anthony Camerlo on Unsplash) Integra LifeSciences has agreed to acquire Acclarent from Johnson & Johnson MedTech’s subsidiary Ethicon for $275m in an all-cash deal. The consideration is subject to standard purchase price adjustments, with an additional $5 million payable upon achieving specific regulatory milestones. Based in California, Acclarent is engaged in the development of ear, nose, and throat (ENT) procedures. Its portfolio includes balloon technologies for sinus dilation, eustachian tube dilation, and surgical navigation systems. The ENT company operates research and development (R&D) facilities in Irvine and Haifa, Israel, and uses third-party manufacturers. Integra LifeSciences president and CEO Jan De Witte said: “This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment. “Acclarent’s culture of pioneering technologies aligns with Integra’s legacy of innovation to transform care and restore patients’ lives.” Acclarent will be integrated into Integra’s Codman Specialty Surgical (CSS) division after the closing of the deal. The deal is expected to enable Integra LifeSciences in becoming a major provider of ENT products and technologies. Currently, the company offers the MicroFrance line of instruments in this ENT category. Integra LifeSciences CSS president Mike McBreen said: “The ENT segment is an anatomical adjacency to neurosurgery. For example, this acquisition will provide opportunities for ENT and neurosurgeons to closely collaborate on tumour care using skull base approaches. “Acclarent’s strong commercial capabilities, R&D expertise, advanced portfolio and deep clinical knowledge will be important assets to Integra, allowing us to deliver future innovation not only within ENT, but also across our other CSS technology platforms.” The transaction is expected to be completed by Q2 of 2024, subject to usual closing conditions and regulatory clearances. Integra LifeSciences’ exclusive financial advisor for the deal is Goldman, Sachs & Co., and its exclusive legal advisor is Morgan, Lewis & Bockius.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.